Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

PTGX / Protagonist Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 PROTAGONIST THERAPEUTICS INC COMMON STOCK Cusip #74366E102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74366E102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 396,120 Item 6: 0 Item 7: 3,071,949 Item 8: 0 Item 9: 3,071,949 Item 11: 14.

PTGX / Protagonist Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 PROTAGONIST THERAPEUTICS INC COMMON STOCK Cusip #74366E102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74366E102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 396,120 Item 6: 0 Item 7: 3,071,949 Item 8: 0 Item 9: 3,071,949 Item 11: 14.

PTGX / Protagonist Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-07 fintel.io
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has 58 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,713,152 shares. Largest shareholders include FMR LLC / Fidelity, Adage Capital Partners GP LLC, Aisling Capital IV, LP, Pharmstandard International S.A., Cormorant Asset Management, LLC, BlackRock Inc. (34-0)

PTGX / Protagonist Therapeutics, Inc. / Aisling Capital IV, LP - AMENDMENT NO. 1 (Passive Investment)

2018-02-07 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer)   Common Stock, par value $0.00001 per share (Title of Class of Securities)   74366E102 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

PTGX / Protagonist Therapeutics, Inc. / Aisling Capital IV, LP - AMENDMENT NO. 1 (Passive Investment)

2018-02-07 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protagonist Therapeutics, Inc. (Name of Issuer)   Common Stock, par value $0.00001 per share (Title of Class of Securities)   74366E102 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus

2018-01-29 marketwatch
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology. (84-1)

PTGX / Protagonist Therapeutics, Inc. 8-K (Current Report)

2018-01-08 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 8, 2017     PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     Delaware   001-37852   98-0505495 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.

Stocks To Watch: CES Headlines Blockbuster Conference Slate

2018-01-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (861-9)

Penumbra (PEN) Forms JV on Virtual Reality in Health Space

2018-01-05 zacks
Penumbra, Inc. (PEN - Free Report) has recently made a major investment in the field of healthcare applications through virtual reality technology. The company has partnered with Sixense Entierprises to form a joint venture (JV) called MVI Health Inc. Sixense Entierprises is a leading provider of VR/AR (Virtual and augmented reality) enterprise solutions. The company with its full-presence platform delivers a more natural and intuitive way to interact in the virtual world. (22-0)

PTGX / Protagonist Therapeutics, Inc. / Adage Capital Partners GP LLC - ADAGE CAPITAL PARTNERS GP, L.L.C. (Passive Investment)

2018-01-04 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Protagonist Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.00001 par value per share (Title of Class of Securities)   74366E102 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ¨ Rule 13d-1(b) ý Rule 13d-1(c) ¨ R

PTGX / Protagonist Therapeutics, Inc. / Adage Capital Partners GP LLC - ADAGE CAPITAL PARTNERS GP, L.L.C. (Passive Investment)

2018-01-04 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Protagonist Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.00001 par value per share (Title of Class of Securities)   74366E102 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ¨ Rule 13d-1(b) ý Rule 13d-1(c) ¨ R

New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails

2018-01-03 zacks
On Jan 2, 2018, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) . The stock carries a Zacks Rank #3 (Hold). (57-0)

Thermo Fisher Buys Phenom-World, Aids Analytical Instruments

2018-01-03 zacks
Thermo Fisher Scientific Inc. (TMO - Free Report) has recently completed the acquisition of desktop scanning electron microscopy (SEM) solutions provider, Phenom-World. Financial terms of this transaction remain undisclosed. (27-0)

PetMed Rides on Solid Reorders & New Orders Amid Competition

2018-01-02 zacks
On Dec 29, we issued an updated research report on PetMed Express, Inc. (PETS - Free Report) . The stock sports a Zacks Rank #1 (Strong Buy). (25-0)

Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%

2017-12-28 zacks
Fate Therapeutics, Inc.  (FATE - Free Report)  was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $3.94–$4.65 in the past one-month time frame, witnessed a sharp increase yesterday. (86-0)


CUSIP: 74366E102